TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65~* Males or females~* type 1 diabetes~* a plan to shift from twice daily glargine or detemir to once daily degludec~* HbA1c \>=7.0%~* Informed consent~Exclusion Criteria:~* Age \<18 or \>65~* HbA1c \<7.0%~* Pregnancy or lactation~* Recent (within 3 months) acute diseases or surgery~* Cancer~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Patients shifting to insulin degludec (Type: None): Patients shifting from twice daily glargine or detemir to once daily degludec. This change in therapy will have to be decided by the diabetologist and the patient, not done for the purpose of the study.
- Patients remaining on twice daily glargine/detemir (Type: None): Patients continuing on twice daily glargine or detemir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Evidence of histo or cytopathology confirmed, advanced NSCLC (with known histology) with the presence of EGFR-activating mutation (exon 19 deletion or the L858R mutation in exon 21).~* It is acceptable for subjects with the presence of the exon 20 T790M mutation together with either EGFR-activating mutation (exon 19 deletion or the L858R mutation in exon 21) to be included in this study~* No prior treatment with systemic therapy for locally advanced or metastatic NSCLC. Minimum of 12 months disease free interval between completion of neoadjuvant/adjuvant systemic therapy and recurrence of NSCLC~* Adequate tissue sample must be available for central analyses.~* Adequate renal, hematologic, liver function.~* ECOG PS of 0-1.~* Radiologically measurable disease.~Exclusion Criteria:~* Any evidence of mixed histology that includes elements of small cell or carcinoid lung cancer.~* Any other mutation other than exon 19 deletion or L858R in exon 21, with or without the presence of the exon 20 T790M mutation.~* Any history of brain metastases or leptomeningeal metastases.~* Any previous anti-cancer systemic treatment of early, locally advanced, or metastatic NSCLC.~* Any surgery(not including minor procedures such as lymph node biopsy), palliative radiotherapy or pleurodesis within 2 weeks of baseline assessments~* Any clinically significant gastrointestinal abnormalities that may impair intake, transit or absorption of the study drug.~* Current enrollment in another therapeutic clinical study.~* History of, or currently suspected, diffuse non-infectious pneumonitis or interstitial lung disease~* Uncontrolled medical disorders.~* Prior malignancy and concurrent malignancy except for non melanoma skin cancer or in-situ cervical cancer with no evidence of active disease.~* Use of narrow therapeutic index drugs that are CYP2D6 substrates from screening to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Dacomitinib (PF-00299804) (Type: EXPERIMENTAL): Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing.
- gefitinib (Type: ACTIVE_COMPARATOR): Gefitinib is provided as 250 mg tablets, continuous oral daily dosing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 3 episodes of urinary incontinence over a 3-day period~* History of Multiple Sclerosis (MS)~* Urinary incontinence not adequately controlled by anticholinergic medication~Exclusion Criteria:~* Current use of intermittent catheter or indwelling catheter to manage urinary incontinence~* Previous or current botulinum toxin therapy of any serotype for any urological condition~* Previous or current botulinum toxin therapy of any serotype for any non-urological condition within the last 12 weeks~* Diagnosis of myasthenia gravis, Eaton-Lambert Syndrome, or Amyotrophic Lateral Sclerosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OnabotulinumtoxinA (Type: EXPERIMENTAL): OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for a second onabotulinumtoxinA 100 U injection.
- Placebo (Normal Saline) (Type: OTHER): Placebo (normal saline) is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for an onabotulinumtoxinA injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Microneedling Daycare Procedure and Tazarotene 0.1% Gel Local Application in Acne Scarring

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with grade 2 to grade 4 atrophic acne scars, classified on the basis of Goodman's Qualitative classification.6~* Should not have undergone any surgical and/or laser treatment for acne scars in the past 1 year.~Exclusion Criteria:~* Active acne~* History of keloidal tendency/hypertrophic or keloidal scarring on the face due to acne~* Facial scars due to reasons other than acne like varicella, trauma, burns etc~* Collagen vascular disease, bleeding disorders~* Any active bacterial , fungal or viral infection over face~* Pregnant and lactating females~* Known hypersensitivity to tazarotene~* Age less than 18 years~* Patients on anticoagulant therapy or aspirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tazarotene gel arm (Type: EXPERIMENTAL): The treatment protocol in this arm will consist of night time application of Tazarotene 0.1% gel during the entire study period. (3 months)
- Microneedling arm (Type: ACTIVE_COMPARATOR): The treatment protocol in this arm will consist of four sessions of microneedling at monthly intervals. (0, 1, 2, 3 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Tadalafil Once a Day in Men With Erectile Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* You are male and aged at least 18 years.~* Have a history of erectile dysfunction (ED)(defined as the consistent inability to achieve and/or maintain an erection sufficient to permit satisfactory sexual intercourse) of at least 3 months duration.~* Agree not to use any other treatment for ED, including herbal and over-the-counter (OTC) medications, during the study~* You agree to make at least four sexual intercourse attempts with the female sexual study partner during the 4-week run-in period without medication~* Your entry laboratory test results and medical tests meet study requirements~* You agree to use the study drug only as instructed by your study doctor and staff and to return any unused study drug and containers at the end of the study or as otherwise instructed by the study doctor.~* If currently using cholesterol lowering medications (for example: statins) or medications to lower blood pressure (example: angiotensin-converting enzyme (ACE) inhibitors or calcium channel blocker medications), you need to be on a stable dose and you and your study doctor do not expect any dose change during the study.~Exclusion Criteria:~* You have received previous or current treatment with tadalafil or any other PDE5 inhibitor.~* Currently receives treatment with doxazosin, nitrates, cancer chemotherapy, or anti-androgens (except finasteride e.g. Propecia™ or Proscar®, or dutasteride e.g. Avodart®).~* You have had significant heart disease as determined by your doctor in charge of this study or a member of the doctor's staff.~* Have a history of significant central nervous system injuries (including stroke or spinal cord injury) within the last 6 months.~* Have a history of loss of vision in one eye because of nonarteritic anterior ischemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tadalafil (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence Tomography

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~(I) 18 - 80 years of age, (II) diagnosed as stable coronary artery disease or acute coronary syndrome during admission (III) undergoing clinically indicated coronary angiography and identified with at least one intermediate lesion (50%-70% diameter stenosis) on de novo coronary arteries, (IV) have an elevated LDL-C values (LDL-C≥100 mg/dL) despite taken rosuvastatin 10 mg/day or atorvastatin 20 mg/day for 2-4 weeks after initiation or with maximally tolerated statin therapy, (V) able to provide written, informed consent.~Exclusion Criteria:~1. Patients who have been treated previously with at least one dose of any anti-PCSK9 monoclonal antibody~2. received target vessel revascularization~3. Known hypersensitivity or have contraindications to any anti-PCSK9 monoclonal antibody or statins~4. Unable to receive OCT imaging tests~5. Known history of hemorrhagic stroke~6. Currently under treatment for cancer~7. Baseline triglyceride \> 400 mg/dl~8. Patients with severe liver or renal dysfunction~9. Pregnant or breast-feeding women~10. Considered by the investigator as inappropriate for this study for any reason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- alirocumab plus statin (Type: EXPERIMENTAL): Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
- standard statin therapy (Type: ACTIVE_COMPARATOR): Patients in the standard statin arm will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day. Statin dose escalation or adding concomitant non-statin lipid-lowering therapy could be considered by their responsible physician to achieve an LDL-C target \<100 mg/dL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulant subjects with Duchenne muscular dystrophy resulting from a mutation in the DMD gene, confirmed by a state-of-the-art DNA diagnostic technique covering all DMD gene exons, including but not limited to MLPA (Multiplex Ligation-dependent Probe Amplification), CGH (Comparative Genomic Hybridisation) or H-RMCA (High-Resolution Melting Curve Analysis), and correctable by GSK2402968-induced DMD exon 51 skipping,~* Males, at least 5 years of age and with a life expectancy of at least 1 year~* Able to rise from floor in ≤7 seconds (without aids/orthoses),~* Able to complete the 6MWD test with a distance of at least 75m~* Receiving glucocorticoids for a minimum of 6 months immediately prior to screening, with no significant change in total daily dosage or dosing regimen for a minimum of 3 months immediately prior to screening and a reasonable expectation that total daily dosage and dosing regimen will not change significantly for the duration of the study~* QTc \<450msec~* On adequate contraception~* Able to comply with and complete all protocol requirements~Exclusion Criteria:~* any additional missing exon for DMD~* Current of history of liver or renal disease or impairment~* Acute illness within 4 weeks of the first dose~* Use of prohibited meds within 6 months of fist dose~* Current participation in any other investigational clinical trial~* Positive hepatitis B surface antigen, hepatitis C antibody test, or human immunodeficiency virus (HIV) test at screening~* Symptomatic cardiomyopathy~* Children in Care

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous regimen; 6mg/kg once weekly (Type: EXPERIMENTAL): Once Weekly
- Intermittent regimen; 6mg/kg twice weekly (Type: EXPERIMENTAL): Twice weekly on 1st, 3rd and 5th weeks, once weekly on 2nd, 4th and 6th weeks, and no active drug on 7th to 10th week of each 10 week cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PROACT - Pre-Operative Arimidex Compared To Tamoxifen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Operable or potentially operable breast cancer~* Invasive breast cancer proven to be hormone-sensitive (ER+/PR+)~* Patients who might benefit from endocrine treatment prior to surgery~* Postmenopausal~* Signed written informed consent~Exclusion Criteria:~* Inoperable breast cancer~* Patient unwilling to undergo surgery~* Any reason why the patient may not be able to conform to study requirements~* Any previous treatment for breast cancer~* Previous Tamoxifen use as a part of breast cancer prevention trials~* Not willing to stop taking drugs that affect sex-hormones such as HRT~* Previous history of breast cancer~* Previous history of invasive malignancy within the last 10 years~* Any other severe disease that may prevent surgery, place the patient at risk, or influence the study results~* Treatment with an experimental drug within the last 3 months~* Risk of transmitting HIV, Hepatitis B or C

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sayana® Press Self-injection Study in Malawi

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Age 18-40, inclusive~* In general good health (participant verbally reports she feels well)~* Able to understand and willing to sign an informed consent document~* Willing to give contact information for follow-up~* Agree to have follow-up visits/interviews~* Willing to be randomized to the self-injection arm or provider-administered injection arm~* Menstrual period started within the past 7 days (for new DMPA users)~* Meet eligibility criteria for receiving DMPA per WHO Medical Eligibility Criteria (MEC)~Exclusion Criteria:~Pregnancy~* Plans to become pregnant in the next 12 months~* Plans to relocate outside the study area in the next 12 months~* Any condition (social or medical) which in the opinion of the investigator would make study participation unsafe or would interfere with adherence to study requirements or complicate data interpretation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- self-injection (Type: ACTIVE_COMPARATOR): Women randomized to this arm will be trained to self-inject Sayana Press at home every three months
- provider injection (Type: ACTIVE_COMPARATOR): Women randomized to this arm will received Sayana press from a family planning provider every three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed squamous cell cancer of the head and neck suitable for treatment with radiotherapy T2, T3, or T4 primary lesions Any N No distant metastasis May also be anaplastic carcinoma, verrucous carcinoma, or transitional cell carcinoma (as of 1/97) No occult primaries (as of 1/97) No adenocarcinomas, lymphomas, or melanomas (as of 1/97) Synchronous head and neck tumors are eligible (tumor with the worse prognosis is entered into study) (as of 1/97) Patients receiving surgery to neck nodes only must be randomized as surgery patients (as of 1/97) Patients with tumors of the oral cavity or oropharynx may additionally elect randomization to nodal irradiation vs. no further therapy provided there is no second primary~PATIENT CHARACTERISTICS: Age: 75 and under for patients electing participation in the nodal vs. no nodal irradiation portion of the study Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Fit for any protocol treatment option Willing to receive any protocol treatment option Prior malignancy allowed provided the treating clinician considers the patient cured~PRIOR CONCURRENT THERAPY: Biologic therapy: No prior therapy Chemotherapy: No prior therapy Endocrine therapy: No prior therapy Radiotherapy: No prior therapy Surgery: Prior biopsy or excision allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remicade in the Treatment of Patients With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~The patients had to fulfill the following four inclusion criteria:~(I) Age between 18 and 60 years, (II) proven diagnosis according to the modified New York criteria 12 for definitive AS, (III) active disease with Bath AS Disease Activity Index (BASDAI) score above 4 and (IV) current or previous treatment with conventional non-steroidal anti-inflammatory drugs (NSAID) in adequate doses without sufficient effect.~Exclusion Criteria:~* current signs or symptoms of severe, progressive or uncontrolled hepatic, hematological, pulmonary, cardiac, neurological or cerebral disease;~* ongoing or past serious infection (including HIV and past or current tuberculosis);~* pregnancy or breast feeding;~* current malignancy or history of malignancy within the past five years;~* congestive heart failure and any contraindication to MRI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Infliximab (Type: None): Patients with active AS defined as BASDAI score above 4 and no exclusion criteria were consecutively included in this single-armed unblinded trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete